Vitespen

Summary

Vitespen (CHEMBL2108060) is a phase-3 clinical-stage unknown; indicated across 16 conditions including renal cell carcinoma and melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 16 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108060
Name	Vitespen
Type	Unknown
Max phase	3

Also known as: HSPPC-96, Vitespen, VITESPEN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

16 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
renal cell carcinoma	3	MONDO:0005086	EFO:0000681
melanoma	3	MONDO:0005105	EFO:0000756
kidney cancer	3	MONDO:0002367	MONDO:0002367
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
glioblastoma	2	MONDO:0018177	EFO:0000519
sarcoma	2	MONDO:0005089	EFO:0000691
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
gliosarcoma	2	MONDO:0016681	EFO:1001465
central nervous system neoplasm	2	MONDO:0006130	EFO:1000158
follicular lymphoma	2	MONDO:0018906	MONDO:0018906
lung carcinoma	2	MONDO:0005138	EFO:0001071
brain neoplasm	2	MONDO:0021211	EFO:0003833
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
ependymoma	1	MONDO:0016698	EFO:1000028
astrocytoma (excluding glioblastoma)	1	MONDO:0019781	EFO:0000272

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	6
PHASE1/PHASE2	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00126178	PHASE3	TERMINATED	Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
NCT00005628	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
NCT00098085	PHASE2	COMPLETED	Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
NCT00293423	PHASE1/PHASE2	COMPLETED	GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
NCT00905060	PHASE2	COMPLETED	HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
NCT01147536	PHASE2	TERMINATED	Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
NCT01814813	PHASE2	TERMINATED	Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
NCT02452281	PHASE1/PHASE2	WITHDRAWN	Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
NCT03018288	PHASE2	TERMINATED	Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
NCT00003025	PHASE1	COMPLETED	Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).